"Thienamycins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Beta-lactam antibiotics that differ from PENICILLINS in having the thiazolidine sulfur atom replaced by carbon, the sulfur then becoming the first atom in the side chain. They are unstable chemically, but have a very broad antibacterial spectrum. Thienamycin and its more stable derivatives are proposed for use in combinations with enzyme inhibitors.
| Descriptor ID |
D013845
|
| MeSH Number(s) |
D02.065.589.099.124.300 D03.633.100.300.124.300
|
| Concept/Terms |
Thienamycins- Thienamycins
- Antibiotics, Thienamycin
- Thienamycin Antibiotics
|
Below are MeSH descriptors whose meaning is more general than "Thienamycins".
Below are MeSH descriptors whose meaning is more specific than "Thienamycins".
This graph shows the total number of publications written about "Thienamycins" by people in this website by year, and whether "Thienamycins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2014 | 1 | 1 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Thienamycins" by people in Profiles.
-
Karlowsky JA, Kazmierczak KM, de Jonge BLM, Hackel MA, Sahm DF, Bradford PA. In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015. Antimicrob Agents Chemother. 2017 09; 61(9).
-
Nichols WW, de Jonge BL, Kazmierczak KM, Karlowsky JA, Sahm DF. In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014). Antimicrob Agents Chemother. 2016 08; 60(8):4743-9.
-
Cies JJ, Moore WS, Dickerman MJ, Small C, Carella D, Chopra A, Parker J. Pharmacokinetics of continuous-infusion meropenem in a pediatric patient receiving extracorporeal life support. Pharmacotherapy. 2014 Oct; 34(10):e175-9.
-
Tsiatsiou O, Iosifidis ?, Katragkou A, Dimou V, Sarafidis K, Karampatakis T, Antachopoulos C, Orfanou A, Tsakris A, Drossou-Agakidou V, Roilides E. Successful management of an outbreak due to carbapenem-resistant Acinetobacter baumannii in a neonatal intensive care unit. Eur J Pediatr. 2015 Jan; 174(1):65-74.
-
Bulik CC, Fauntleroy KA, Jenkins SG, Abuali M, LaBombardi VJ, Nicolau DP, Kuti JL. Comparison of meropenem MICs and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods. J Clin Microbiol. 2010 Jul; 48(7):2402-6.
-
Vera-Cabrera L, Campos-Rivera MP, Escalante-Fuentes WG, Pucci MJ, Ocampo-Candiani J, Welsh O. In vitro activity of ACH-702, a new isothiazoloquinolone, against Nocardia brasiliensis compared with econazole and the carbapenems imipenem and meropenem alone or in combination with clavulanic acid. Antimicrob Agents Chemother. 2010 May; 54(5):2191-3.
-
Sahm D. In vitro activity of doripenem. Clin Infect Dis. 2009 Aug 15; 49 Suppl 1:S11-6.
-
Brett-Major DM, Baraniak SM, Gilhooly JE, Christensen RL, Grant GT, Armonda RA, Ganesan A. Foreign-body reaction mimicking postneurosurgical infection after cranioplasty. Mil Med. 2008 Jul; 173(7):697-9.
-
Jones ME, Thornsberry C, Livermore DM, Sahm DF. Prevalence of Acinetobacter spp. isolates with reduced susceptibility to imipenem, as determined by a USA-wide electronic surveillance network. J Antimicrob Chemother. 1999 Mar; 43(3):429-31.
-
Hemsell DL, Martens MG, Faro S, Gall S, McGregor JA. A multicenter study comparing intravenous meropenem with clindamycin plus gentamicin for the treatment of acute gynecologic and obstetric pelvic infections in hospitalized women. Clin Infect Dis. 1997 Feb; 24 Suppl 2:S222-30.